12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enhanced TCR therapy for MM: Additional Phase I/II data

Data from 20 evaluable MM patients in a single-arm, open-label, U.S. Phase I/II trial showed that enhanced TCR therapy given in conjunction with ASCT led to an ORR of 77% at day 100. Of the 20 patients treated to date, 13 have ongoing responses and 7 have progressed. In patients who progressed, Adaptimmune said...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >